Tafenoquine: a toxicity overview

References

• Mühlens P. Die Behandlung der natürlichen menschlichen Malaria-Infektion mit Plasmochin. Naturwissenschaften. 1926; 14:1162–1166.
   Google Scholar
• Zottig VE, Carr KA, Clarke JG, et al. Army antimalarial drug development: an advanced development case study for tafenoquine. Mil Med. 2020;185(Supplement_1):617–623. .
   PubMedGoogle Scholar
• Brueckner RP, Lasseter KC, Lin ET, et al. First-time-in-humans safety and pharmacokinetics of wr 238605, a new antimalarial. Am J Trop Med Hyg. 1998;58(5): 645–649.
   PubMed Web of Science ®Google Scholar
• Haston JC, Hwang J, Tan KR. Guidance for using tafenoquine for prevention and antirelapse therapy for Malaria - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(46):1062–1068.
   PubMed Web of Science ®Google Scholar
• Velez ID, Tran TH, Martin A, et al. A randomized, open-label, non-comparative multicenter study to assess the pharmacokinetics, safety, and efficacy of tafenoquine in the treatment of pediatric subjects with Plasmodium vivax malaria (TEACH study). Am Soc Trop Med Hyg. 2020;427.
   PubMedGoogle Scholar
• Gilder ME, Hanpithakphong W, Hoglund RM, et al. Primaquine pharmacokinetics in lactating women and breastfed infant exposures. Clin Infect Dis. 2018;67(7): 1000–1007. .
   PubMed Web of Science ®Google Scholar
• Rueangweerayut R, Bancone G, Harrell EJ, et al. Hemolytic potential of tafenoquine in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers. Am J Trop Med Hyg. 2017;97(3): 702–711. .
   PubMed Web of Science ®Google Scholar
• Shanks GD, Oloo AJ, Aleman GM, et al. A New Primaquine Analogue, Tafenoquine (WR 238605), for Prophylaxis against Plasmodium falciparum Malaria. Clin Infect Dis. 2001;33(12): 1968–1974. .
   PubMed Web of Science ®Google Scholar
• Ponsa N, Sattabongkot J, Kittayapong P, et al. Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of plasmodium vivax in Thailand. Am J Trop Med Hyg. 2003;69(5):542–547. .
   PubMed Web of Science ®Google Scholar
• Dow G, Smith B. The blood schizonticidal activity of tafenoquine makes an essential contribution to its prophylactic efficacy in nonimmune subjects at the intended dose (200 mg). Malar J. 2017;16(1):1–9.
   PubMedGoogle Scholar
• Fukuda MM, Krudsood S, Mohamed K, et al. A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. PLoS One. 2017;12(11):e0187376. .
   PubMed Web of Science ®Google Scholar
• Chu CS, Bancone G, Moore KA, et al. Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med. 2017;14(2):e1002224. .
   PubMed Web of Science ®Google Scholar
• Hockwald RS, Arnold J, Clayman CB, et al. Toxicitiy of Primaquine in Negroes. J Am Med Assoc. 1952;149(17):1568–1570. .
   PubMed Web of Science ®Google Scholar
• Tarlov AR, Brewer GJ, Carson PE, et al. Primaquine sensitivity. Glucose-6-phosphate dehydrogenase deficiency: an inborn error of metabolism of medical and biological significance. Arch Intern Med. 1962;109(2):209–234. .
   PubMedGoogle Scholar
• Howes RE, Piel FB, Patil AP, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339. .
   PubMed Web of Science ®Google Scholar
• Hill DR, Baird JK, Parise ME, et al. Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg. 2006;75(3):402–415. .
   PubMed Web of Science ®Google Scholar
• Cohen RJ, Sachs JR, Wicker DJ, et al. Methemoglobinemia provoked by malarial chemoprophylaxis in Vietnam. N Engl J Med. 1968;279(21):1127–1131. .
   PubMed Web of Science ®Google Scholar
• Clayman CB, Arnold J, Hockwald RS, et al. Toxicity of Primaquine in Caucasians. J Am Med Assoc. 1952;149(17):1563–1568. .
   PubMed Web of Science ®Google Scholar
• Alving BYALFS, Craige B, Jones R, et al. Pentaquine (SN-13,276), a therapeutic agent effective in reducing the relapse rate in vivax malaria. J Clin Investig. 1947;27(3 Pt 2):25–33. .
   Web of Science ®Google Scholar
• Edgcomb JH, Arnold J, Yount EH Jr., et al. Primaquine, SN 13272, a new curative agent in vivax malaria; a preliminary report. J Natl Malar Soc. 1950;9:285–292.
   PubMedGoogle Scholar
• Douglas NM, Poespoprodjo JR, Patriani D, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Med. 2017;14(8):1–19. .
   Web of Science ®Google Scholar
• Ashley EA, Recht J, White NJ. Primaquine: the risks and the benefits. Malar J. 2014;13(1):418.
   PubMed Web of Science ®Google Scholar
• Garfield RM, Vermund SH. Changes in malaria incidence after mass drug administration in Nicaragua. Lancet. 1983;322(8348):500–503.
   Google Scholar
• Hsiang MS, Hwang J, Tao AR, et al. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J. 2013;12(1):383. .
   PubMedGoogle Scholar
• Kondrashin A, Baranova AM, Ashley EA, et al. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13(1):51. .
   PubMedGoogle Scholar
• Poirot E, Skarbinski J, Sinclair D, et al. Mass drug administration for malaria. Cochrane Database Syst Rev. 2013;Article number:CD008846.
   Google Scholar
• Charles BG, Miller AK, Nasveld PE, et al. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother. 2007;51(8):2709–2715. .
   PubMed Web of Science ®Google Scholar
• Edstein MD, Kocisko DA, Brewer TG, et al. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. Br J Clin Pharmacol. 2001;52(6):663–670. .
   PubMed Web of Science ®Google Scholar
• Thakkar N, Green JA, Koh GCKW, et al. Population pharmacokinetics of tafenoquine, a novel antimalarial. Antimicrob Agents Chemother. 2018;62(11):e00711–18. .
   PubMed Web of Science ®Google Scholar
• Edstein MD, Kocisko DA, Walsh DS, et al. Plasma concentrations of tafenoquine, a new long-acting antimalarial agent, in Thai soldiers receiving monthly prophylaxis. Clin Infect Dis. 2003;37(12):1654–1658. .
   PubMed Web of Science ®Google Scholar
• Milner EE, Berman J, Caridha D, et al. Cytochrome P450 2D-mediated metabolism is not necessary for tafenoquine and primaquine to eradicate the erythrocytic stages of Plasmodium berghei. Malar J. 2016;15(1):1–11. .
   PubMedGoogle Scholar
• Marcsisin SR, Sousa JC, Reichard GA, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014;13(1):1–9. .
   PubMedGoogle Scholar
• St Jean PL, Xue Z, Carter N, et al. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial. Malar J. 2016;15(1):97. .
   PubMed Web of Science ®Google Scholar
• Miller AK, Harrell E, Ye L, et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol. 2013;76(6):858–867. .
   PubMed Web of Science ®Google Scholar
• Green JA, Mohamed K, Goyal N, et al. Pharmacokinetic interactions between tafenoquine and dihydroartemisinin-piperaquine or artemether-lumefantrine in healthy adult subjects. Antimicrob Agents Chemother. 2016;60:7321–7332.
   PubMed Web of Science ®Google Scholar
• Change in Krintafel (tafenoquine) label. 2020 [cited 2020 Jul 30]. Available from: https://www.cdc.gov/malaria/new_info/2020/tafenoquine_2020.html
   Google Scholar
• Baird JK, Sutanto I, Soebandrio A, et al. Evaluation of the efficacy and safety of tafenoquine co-administered with dihydroartemisinin-piperaquine for the radical cure (anti-relapse) of Plasmodium vivax malaria in Indonesia - INSPECTOR study. Am Soc Trop Med Hyg. 2020;427.
   PubMedGoogle Scholar
• Kitchener S, Nasveld P, Edstein MD. Short report: tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg. 2007;76(3):494–496.
   PubMed Web of Science ®Google Scholar
• Nasveld P, Kitchener S, Edstein M, et al. Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel. Trans R Soc Trop Med Hyg. 2002;96(6):683–684. .
   PubMed Web of Science ®Google Scholar
• Elmes NJ, Nasveld PE, Kitchener SJ, et al. The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific. Trans R Soc Trop Med Hyg. 2008;102(11):1095–1101. .
   PubMed Web of Science ®Google Scholar
• Duparc S, Chalon S, Miller S, et al. Neurological and psychiatric safety of tafenoquine in Plasmodium vivax relapse prevention: A review. Malar J. 2020;19(1):1–18. .
   PubMed Web of Science ®Google Scholar
• Nasveld PE, Edstein MD, Reid M, et al. Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects. Antimicrob Agents Chemother. 2010;54(2):792–798. .
   PubMed Web of Science ®Google Scholar
• Lacerda MVG, Llanos-Cuentas A, Krudsood S, et al. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019;380(3):215–228. .
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Lacerda MVG, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383(9922):1049–1058. .
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. N Engl J Med. 2019;380(3):229–241. .
   PubMed Web of Science ®Google Scholar
• Novitt-Moreno A, Ransom J, Dow G, et al. Tafenoquine for malaria prophylaxis in adults: an integrated safety analysis. Travel Med Infect Dis. 2017;17:19–27.
   PubMed Web of Science ®Google Scholar
• FDA adverse event reporting system (FAERS) public dashboard. 2020 [cited 2020 Jul 10]. Available from: https://fis.fda.gov/sense/app/d10be6bb-494e-4cd2-82e4-0135608ddc13/sheet/6b5a135f-f451-45be-893d-20aaee34e28e/state/analysis
   Google Scholar
• Lüllmann H, Lüllmann-rauch R, Wassermann O, et al. Drug-Induced phospholipidoses. Crit Rev Toxicol. 1975;4:185–218.
   Google Scholar
• Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol. 1997;25(1):53–60.
   PubMed Web of Science ®Google Scholar
• Raizman MB, Hamrah P, Holland EJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. 2017;62(3):286–301. .
   PubMed Web of Science ®Google Scholar
• Ackert J, Mohamed K, Slakter JS, et al. Randomized placebo-controlled trial evaluating the opthalmic safety of single-dose tafenoquine in healthy volunteers. Drug Saf. 2019;42(9):1103–1114. .
   PubMed Web of Science ®Google Scholar
• Warrasak S, Euswas A, Fukuda MM, et al. Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure. Int Ophthalmol. 2018;39(8):1767–1782. .
   PubMed Web of Science ®Google Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549–558.
   PubMed Web of Science ®Google Scholar
• Funck-Brentano C, Ouologuem N, Duparc S, et al. Evaluation of the effects on the QT-interval of 4 artemisinin-based combination therapies with a correction-free and heart rate-free method. Sci Rep. 2019;9(1):1–8. .
   PubMedGoogle Scholar
• Chan XHS, Win YN, Mawer LJ, et al. Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infect Dis. 2018;18(8):913–923.
   PubMed Web of Science ®Google Scholar
• Watson JA, Tarning J, Hoglund RM, et al. Concentration-dependent mortality of chloroquine in overdose. Elife. 2020; 9:e58631.
   Google Scholar
• Kim K-S, Lee H-A, Cha S-W, et al. Blockade of hERG K+ channel by antimalarial drug, primaquine. Arch Pharmacol Res. 2010;33(5):769–773.
   PubMed Web of Science ®Google Scholar
• Orta-Salazar G, Bouchard RA, Morales-Salgado F, et al. Inhibition of cardiac Na+ current by primaquine. Br J Pharmacol. 2002;135(3):751–763. .
   PubMed Web of Science ®Google Scholar
• Green JA, Patel AK, Patel BR, et al. Tafenoquine at therapeutic concentrations does not prolong Fridericia-corrected QT interval in healthy subjects. J Clin Pharmacol. 2014;54(9): 995–1005. .
   PubMed Web of Science ®Google Scholar
• Lee CC, Kinter LD, Heiffer MH. Subacute toxicity of primaquine in dogs, monkeys, and rats. Bull World Health Organ. 1981;59:439–448.
   PubMed Web of Science ®Google Scholar
• Hale BR, Owusu‐Agyei S, Fryauff DJ, et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Tafenoquine for Weekly Prophylaxis against Plasmodium falciparum. Clin Infect Dis. 2003;36(5):541–549. .
   PubMed Web of Science ®Google Scholar
• Walsh DS, Looareesuwan S, Wilairatana P, et al. Randomized Dose-Ranging Study of the Safety and Efficacy of WR 238605 (Tafenoquine) in the Prevention of Relapse of Plasmodium vivax Malaria in Thailand. J Infect Dis. 1999;180(4): 1282–1287. .
   PubMed Web of Science ®Google Scholar
• Howes RE, Dewi M, Piel FB, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12(1):418. .
   PubMedGoogle Scholar
• Gómez-Manzo S, Marcial-Quino J, Vanoye-Carlo A, et al. Glucose-6-phosphate dehydrogenase: update and analysis of new mutations around the world. Int J Mol Sci. 2016;17:2069. doi:10.3390/ijms17122069.
   Web of Science ®Google Scholar
• Beutler E. G6PD deficiency. Blood. 1994;84(11):3613–3636.
   PubMed Web of Science ®Google Scholar
• Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine, II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med. 1954;44:171–176.
   PubMed Web of Science ®Google Scholar
• Bancone G, Malleret B, Suwanarusk R, et al. Asian G6PD-mahidol reticulocytes sustain normal plasmodium vivax development. J Infect Dis. 2017;216(2):263–266.
   PubMed Web of Science ®Google Scholar
• Chu CS, Phyo AP, Turner C, et al. Chloroquine versus dihydroartemisinin-piperaquine with standard High-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria. Clin Infect Dis. 2018;68(8):1311–1319.
   Web of Science ®Google Scholar
• Walsh DS, Wilairatana P, Tang DB, et al. Randomized Trial of 3-Dose Regimens of Tafenoquine (WR238605) versus Low-Dose Primaquine for Preventing Plasmodium vivax Malaria Relapse. Clin Infect Dis. 2004;39(8):1095–1103.
   PubMed Web of Science ®Google Scholar
• Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27:25–61.
   PubMed Web of Science ®Google Scholar
• Stępień KB, Wilczok T. Studies of the mechanism of chloroquine binding to synthetic dopa-melanin. Biochem Pharmacol. 1982;31(21):3359–3365.
   PubMed Web of Science ®Google Scholar
• Tanenbaum L, Tuffanelli DL. Antimalarial agents. Arch Dermatol. 1980;116(5):587–591.
   PubMedGoogle Scholar
• Recht J, Ashley EA, White NJ Safety of 8-aminoquinoline antimalarial medicines. World Heal. Organ. Geneva: World Health Organization; 2014 [cited 2020 Jul 10]. Available from: https://www.who.int/malaria/publications/atoz/9789241506977/en/
   Google Scholar
• Thriemer K, Bobogare A, Ley B, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN vivax working group. Malar J. 2018;17(1):241. .
   PubMedGoogle Scholar
• Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39(9):1336–1345.
   PubMed Web of Science ®Google Scholar